MedTrace Logo

Envafolimab Combined With Chemotherapy in Metastatic or Recurrent Gastric Adenocarcinoma

NCT05237349 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 38

Last updated 2024-01-05

No results posted yet for this study

Summary

The objective is to investigate the efficacy and safety of Envafolimab combined with chemotherapy in the treatment of metastatic or recurrent gastric adenocarcinoma.

Conditions

  • Metastatic or Recurrent Gastric Adenocarcinoma

Interventions

DRUG

Envafolimab

300mg,sc,d1,Q3W

DRUG

Oxaliplatin

130mg/m2, iv,d1,Q3W

DRUG

S1

40mg/m2, op,bid,d1-14,Q3W

Sponsors & Collaborators

  • Zhangjiagang First People's Hospital

    collaborator OTHER

  • Liangjun Zhu M.M.

    lead OTHER

Principal Investigators

  • Liangjun Zhu · Jiangsu Cancer Institute & Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-03-01
Primary Completion
2024-12-01
Completion
2024-12-01

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05237349 on ClinicalTrials.gov